{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:20:16Z","timestamp":1790713216919,"version":"4.1.0"},"reference-count":22,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T00:00:00Z","timestamp":1701129600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T00:00:00Z","timestamp":1701129600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["headachejournal.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Headache"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>We evaluated galcanezumab for migraine prevention in patients who met International Classification of Headache Disorders, 3rd edition criteria for menstrually related migraine (MRM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients were identified post hoc from three double\u2010blind, randomized, phase 3 clinical trials in patients with episodic migraine. Patients completed a 1\u2010month prospective baseline period and up to 6\u2009months (EVOLVE\u20101 and \u20102, studies pooled) of double\u2010blind treatment with galcanezumab (120\u2009mg\/month) or placebo. Menses and headache information were recorded by electronic daily diary. Patients with a migraine attack starting during the 5\u2010day perimenstrual interval (first day of bleeding \u00b1\u20092\u2009days) for \u22652 of their first three diary\u2010recorded menstrual cycles were categorized as having MRM. The primary efficacy measure was mean change in monthly migraine headache days from baseline, averaged over Months 4 through 6. Response rates, change in monthly perimenstrual migraine headache days, monthly non\u2010perimenstrual migraine headache days, and quality of life were also assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Post hoc MRM analysis criteria were met by 462\/1133 women (41%). Mean (standard deviation) baseline monthly migraine headache days were 9.7 (\u00b13.1;\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009146) for galcanezumab\u2010treated patients and 9.6 (\u00b12.8;\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009316) for placebo\u2010treated patients. The mean change (standard error [SE]) in migraine headache days over Months 4 through 6 was \u22125.1\u2009days (\u00b10.39) for galcanezumab versus \u22123.2 (\u00b10.35) for placebo (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). The mean change (SE) in perimenstrual migraine headache days over Months 4 through 6 was \u22120.75\u2009days (\u00b10.08) for galcanezumab versus \u22120.49 (\u00b10.07) for placebo (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.004). For migraine headache days outside the perimenstrual period, the mean change in migraine headache days was \u22124.6 (\u00b10.38) for galcanezumab and\u2009\u22122.8 (\u00b10.33) for placebo (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Improvements in response rates and the Migraine\u2010Specific Quality of Life Questionnaire were also observed over Months 4 through 6.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Galcanezumab was effective for migraine prevention in women with MRM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/head.14652","type":"journal-article","created":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T23:58:27Z","timestamp":1701215907000},"page":"179-187","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Effect of galcanezumab in women with episodic migraine meeting criteria for menstrually related migraine: A post hoc analysis of\n                    <scp>EVOLVE<\/scp>\n                    \u20101 and\n                    <scp>EVOLVE<\/scp>\n                    \u20102"],"prefix":"10.1111","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4116-9828","authenticated-orcid":false,"given":"E. Anne","family":"MacGregor","sequence":"first","affiliation":[{"name":"Centre for Reproductive Medicine, St\u00a0Bartholomew's Hospital  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose","family":"Okonkwo","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1316-6064","authenticated-orcid":false,"given":"Holland C.","family":"Detke","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pepa","family":"Polavieja","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria S.","family":"Fernandes","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena M.","family":"Pavlovic","sequence":"additional","affiliation":[{"name":"Albert Einstein College of Medicine, Montefiore Headache Center  Bronx New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,11,28]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756285609335537"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01167-6"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2020.07.005"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012741"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30482-8"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102413507637"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12978"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2004.00741.x"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-015-0503-y"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/03331024221099031"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012723"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-018-0003-1"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-021-00544-2"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418779543"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2018.1212"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aww015"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15436-0"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102413485658"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-007-9217-1"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182535d20"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207114"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.14652","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/head.14652","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.14652","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T10:33:34Z","timestamp":1771324414000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/head.14652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,28]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1111\/head.14652"],"URL":"https:\/\/doi.org\/10.1111\/head.14652","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,28]]},"assertion":[{"value":"2023-03-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}